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Background: Patients with bipolar disorder experience sleep disturbance, even in euthymic phases. Changes in
sleep pattern are frequent signs of a new episode of (hypo)mania or depression. Cognitive behavioral therapy for
insomnia (CBT-I) is an effective treatment for primary insomnia, but there are no published results on the effects of
CBT-I in patients with bipolar disorder. In this randomized controlled trial, we wish to compare CBT-I and treatment
as usual with treatment as usual alone to determine its effect in improving quality of sleep, stabilizing minor mood
variations and preventing new mood episodes in euthymic patients with bipolar disorder and comorbid insomnia.
Methods: Patients with euthymic bipolar I or II disorder and insomnia, as verified by the Structured Clinical
Interview for DSM Disorders (SCID-1) assessment, will be included. The patients enter a three-week run-in phase in
which they complete a sleep diary and a mood diary, are monitored for seven consecutive days with an actigraph
and on two of these nights with polysomnography in addition before randomization to an eight-week treatment
trial. Treatment as usual consists of pharmacological and supportive psychosocial treatment. In this trial, CBT-I will
consist of sleep restriction, psychoeducation about sleep, stabilization of the circadian rhythm, and challenging and
correcting sleep state misperception, in three to eight sessions.
Discussion: This trial could document a new treatment for insomnia in bipolar disorder with possible effects on
sleep and on stability of mood. In addition, more precise information can be obtained about the character of sleep
disturbance in bipolar disorder.
Trial registration: ClinicalTrials.gov: NCT01704352.
Keywords: Bipolar disorder type I and II, CBT-I, Cognitive behavioral therapy, Euthymic, Insomnia, Randomized
controlled trialBackground
Bipolar disorder (previously known as manic-depressive
illness) has been ranked seventh among the worldwide
burden of nonfatal diseases [1], and is among the most
costly disorders to affect human beings [2]. In many
patients, bipolar disorder has a chronic and remitting
nature characterized by periods of depression and periods* Correspondence: mette.steinan@ntnu.no
1Department of Neuroscience, Norwegian University of Science and
Technology (NTNU), Trondheim, Norway
2Østmarka Department of Psychiatry, St. Olav’s University Hospital,
Trondheim, Norway
© 2014 Steinan et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
waiver (http://creativecommons.org/publicdom
stated.of hypomania or mania, and is associated with disability in
social and occupational function.
Between 50% and 100% of patients with bipolar dis-
order have been found to suffer from sleep disturbance,
even in euthymic phases [3]. Sleep could be a key factor
in bipolar disorder, as sleep has been shown to be vital
for emotional regulation, and a change in sleep is one of
the most frequent first signs of a new episode of (hypo)
mania or depression [3].
The main interventions for sleep disturbances in bipolar
disorder are regulation of the pharmacological treatment
and focusing on circadian regularity in psychosocial treat-
ments [3]. Psychosocial treatments for bipolar disorder areLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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lifestyle changes, such as regulation of activity and sleep,
reduced use of alcohol and substances, monitoring signs
of new episodes, support, and the formation of a plan for
early intervention. Monitoring symptoms and early in-
tervention for signs of mania are the only elements in the
treatment packages that have been tested and found
effective as a stand-alone intervention [4,5].
Insomnia is defined as difficulty in initiating or main-
taining sleep, or nonrestorative sleep. The disturbed sleep
or associated daytime fatigue causes distress or impair-
ment [6]. Insomnia may be a primary disorder or it may
be comorbid with other disorders. Insomnia affects 10% to
12% of the general population [7-9]. Despite focusing on
sleep and circadian regularity in existing treatments of
bipolar disorder, there may be room for improvement
in the treatment of sleep [3]. To our knowledge, stud-
ies describing more focused interventions using well-
documented techniques in treating insomnia in bipolar
patients have not been published.
Several trials have demonstrated that cognitive behav-
ioral therapy for insomnia (CBT-I) is an effective treat-
ment for primary insomnia [10]. It can be superior to
pharmacological treatment in both short-term and long-
term perspectives [11]. Although evidence of the effective-
ness of CBT-I has existed for more than 20 years, it has
not been introduced to patients who also suffer from bipo-
lar disorder [12]. Between-group effect sizes for CBT-I are
usually in the range of 1.0 to 1.6, as measured with the
Insomnia Severity Index (ISI) [12,13].
Although it is well documented that sleep is disturbed
in bipolar disorder, there is less knowledge about how
sleep is disturbed [3]. There is evidence to suggest that
sleep in bipolar disorder is characterized by circadian
rhythm disturbance, as in patients with delayed sleep
phase syndrome, as well as by maladaptive cognitive and
behavioral strategies, as in otherwise healthy individuals
with insomnia [3]. Descriptive studies of frequency and
type of sleep disturbance in euthymic patients with bipolar
disorder are needed to improve treatment. Data from this
trial will be used in a micro- and macroscopic description
of the character of sleep disturbance in patients with
euthymic bipolar disorder and comorbid sleep disturbance.
Sleep diaries, actigraphy, and, more seldom, polysomno-
graphy have traditionally been used to measure the effects
of sleep interventions. Polysomnography is considered the
best objective monitoring system and the only way to as-
sess the constitution of sleep stages, including changes in
slow wave sleep and rapid eye movement sleep, whereas
subjective descriptions of sleep quality are better predic-
tors of functional impairment and emotional distress [11].
The aims of this randomized controlled trial are to com-
pare CBT-I and treatment as usual (TAU) with treatment
as usual alone in improving quality of sleep, stabilizingminor mood variations, and preventing new mood epi-
sodes in euthymic patients with bipolar disorder and
comorbid insomnia. In addition, the study will compare
the use of sleep diaries, actigraphy, and polysomnogra-




The study is a randomized controlled trial aimed to study
the efficacy of CBT-I in euthymic bipolar disorder patients
with comorbid insomnia compared with TAU. Patients will
be recruited from the Department of Psychiatry, St. Olav’s
University Hospital, Trondheim, Norway. They must fulfill
criteria for SCID-1 (Structured Clinical Interview for DSM
Disorders) verified bipolar I or II disorder and be euthymic,
as defined by a score on the Montgomery Åsberg
Depression Rating Scale (MADRS) not higher than 13
or by a score on the Young Mania Rating Scale (YMRS)
not higher than seven. In addition, patients must fulfill
the DSM-IV diagnosis criteria of ‘insomnia related to
another mental disorder’ as assessed by the Insomnia
Interview Schedule (IIS) [14]. Patients will not be ac-
cepted if they meet any of the following exclusion cri-
teria: they are in an affective episode; they work night
shifts; they have an ongoing alcohol or substance abuse
problem, or sleep apnea or other confounding sleep dis-
orders, or medical conditions that may account for a
sleep disturbance; or they have conditions or cognitive
impairments incompatible with participation. Patients
must not have been in a defined episode in the previous
month or have been hospitalized in the previous two
months. Any prophylactic medication of the partici-
pants must be accepted by a doctor in the study.
Patients meeting criteria for inclusion will enter a run-
in phase consisting of three weeks, during which they
will complete a sleep and mood diary and a register
of adherence to medication. In the last of these three
weeks, they will be monitored for seven consecutive days
with an actigraph and for two nights using ambulatory
polysomnography. The patients will be assigned a pa-
tient number and sign a consent form after receiving
oral and written information about the study prior to
undergoing study procedures. The patients will receive
US $85 in compensation for each polysomnography ses-
sion, and another US $85 in compensation for transport
costs and other expenses related to participation. Those
patients who are able to complete the three-week run-in
phase and meet diagnostic criteria for insomnia will then
be randomized to the treatment trial. Figure 1 summarizes
the study design and Table 1 summarizes the measures to
be used in the trial. Patients who have not received psy-
choeducation for bipolar disorder, either in groups or indi-
vidually, will be offered such psychoeducation, to ensure
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Figure 1 Study design.
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order. The patients will be rediagnosed for insomnia 6
months after treatment termination. The results of the
nights recorded with sleep diaries, actigraphs, and poly-
somnography will be compared in order to describe the
accuracy and clinical utility of sleep diaries and actigraphy
compared with polysomnography in bipolar disorder. Par-
ticipants in the TAU group will be offered standard treat-
ment at the sleep clinic for their sleep disturbances at the
end of the six-month follow-up. The included bipolar dis-
order patients will also be included in a descriptive study
of bipolar patients in Norway, the Bipolar Research and
Innovation Network- Norway (BRAIN-Norway).
Measures
Measures of affective disturbance
Network Entry Questionnaire for Bipolar Disorder
(NEQ) This is a Norwegian adaptation of NEQ used in
the Bipolar Collaborative Network and in the Bipolar Re-
search and Innovation Network, Norway. The NEQ gives
a clinical description of the bipolar disorder, comorbidity,
treatment history, and sociodemographics [15,16].
Montgomery Åsberg Depression Rating Scale (MADRS)
This is an interview-based questionnaire used to assess
the level of depression [17]. Setting the cut-off value to
13 at baseline, instead of 9, takes into account that most
participants in this study will probably score up to four
points on the question regarding sleep.
Young Mania Rating Scale (YMRS) This is an interview-
based questionnaire used to assess level of mania orhypomania [18]. Setting the cut-off value to 7, instead of
6, which is normally used, takes into account that most
participants in this study will probably score two points
on the question regarding sleep.
Beck Depression Inventory (BDI) This is a self-report
questionnaire used to assess the level of depression [19]. It
will be used before and after treatment, and at follow-up.
Beck Anxiety Inventory (BAI) This is a self-report ques-
tionnaire used to assess the level of anxiety [20]. It will
be used before and after treatment, and at follow-up.
Altman Self-Rating Mania Scale This is a self-report
questionnaire used to assess the amount of mania symp-
toms [21]. It will be used before and after treatment, and
at follow-up.
Dated registration of changes in medication, hospitaliza-
tions, and other changes in care will be recorded from
the start, after treatment (eighth week) and at the six-
month follow-up.
Measures of sleep disturbance and daytime impairment
We will use the recommendations for a standard research
assessment of insomnia published by Buysse et al. [22].
Polysomnography Sleep will be recorded with standard
Somnoscreen equipment (EEG, EMG (submental and
tibial, EOG, airflow, respiration, position and oxygen sat-
uration), analyzed with Domino software. This will be
done on two nonconsecutive nights during the last week
Table 1 Measures in the treatment trial




















Insomnia criteria X X X
Registrations
Changes in medication X X X X
Hospital admissions X X X X
Consent X
Objective measures
Actigraphy X X X
Polysomnography X X X
Patient-reported measures
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week) and one night at the six-month follow-up.
Actigraphy Movement during sleep will be measured
and stored continuously using a small wristwatch-likedevice. Actigraphs from Philips Respironics will be used
and analyzed with Actiwatch Spectrum and the latest
version of Actiware software. This will be done for one
week at the end of the run-in phase, one week post-
treatment (eighth week) and one week at the six-month
follow-up. The medium sensitivity setting will be used,
with an epoch length of 30 s.
Sleep diary This will be kept daily during the three
weeks before randomization, daily for two weeks at
treatment termination and daily for two weeks at the
six-month follow-up [14]. The sleep diary will include
a rating of mood. The sleep diary will be kept in ac-
cordance with the consensus recommendation for sleep
diaries [23].
Insomnia Severity Index (ISI) This is a self-report
questionnaire used to assess the level of insomnia sever-
ity [24]. Patients will complete the ISI before and after
treatment and at the six-month follow-up. The ISI is the
primary outcome measure.
The Short-Form Health Survey (SF-36) This is a self-
report questionnaire used to assess quality of life [25]. It
will be used before and after treatment, and at follow-
up.
Flinders Fatigue Scale (FFS) This is a self-report ques-
tionnaire used to assess the degree of fatigue [26]. It will
be used before and after treatment, and at follow-up.
Morningness-Eveningness Questionnaire (MEQ) [27]
This is a self-report questionnaire used to assess diurnal
preference and circadian disturbance. It will be used be-
fore and after treatment, and at follow-up.
Dysfunctional Attitudes and Beliefs about Sleep
(DBAS-16) [28] This is a self-report questionnaire used
to assess the degree to which patients hold dysfunctional
beliefs about sleep. It will be used before and after treat-
ment, and at follow-up.
Sleep-Related Behaviors Questionnaire (SRBQ) [29]
This is a self-report questionnaire used to assess the de-
gree to which patients engage in safety behaviors to cope
with poor sleep. It will be used before and after treat-
ment, and at follow-up.
Insomnia Daytime Worry Scale (IDWS) [30] This is a
self-report questionnaire used to assess the amount of
time patients spend worrying about sleep-related topics
during the day. It will be used before and after treat-
ment, and at follow-up.
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naire used to determine how often the patient engages in
behaviors that are considered to be incompatible with
good sleep hygiene [31]. It will be used before and after
treatment, and at follow-up.
Data collection and randomization
Clinical interviews and registrations will be conducted
by a psychiatrist, medical doctor, or clinical psychologist
at the Bipolar Clinic, Østmarka Department of Psychiatry,
St. Olav’s University Hospital, Trondheim, Norway. The
insomnia diagnosis will be assessed before randomization,
and at a six-month follow-up. The polysomnographs will
be administered by the Department of Clinical Neuro-
physiology at St. Olav’s University Hospital and assessed
by a blinded medical doctor. The actigraphy recordings
will be administered by the clinician in charge of treat-
ment of each patient. Except for the daily assessments of
mood and sleep, the patient-reported measures will be col-
lected using a secure internet-based interface, but patients
will be given the option of completing the paper-version
of the self-reported measures at the clinic instead.
Patients will be randomized to CBT-I or TAU by a web-
based system developed and administered by the Unit
of Applied Clinical Research, Norwegian University of
Science and Technology (NTNU), Trondheim, Norway.
Eligible patients who have signed the consent form and
fulfill criteria for participation will be randomized sequen-
tially, in blocks of variable size to ensure an even alloca-
tion throughout the study.
Treatments
Treatment as usual (TAU) This is pharmacological and
supportive psychosocial treatment according to the
needs and current regime of the patient. The amount of
contact with health care professionals outside of our de-
partment will be registered. In addition, patients will be
offered biweekly consultations with either a psychologist
or a medical doctor from our study.
Cognitive behavioral therapy for insomnia (CBT-I)
[14] This is a multicomponent treatment usually con-
sisting of one or more of the following interventions:
sleep restriction therapy, psychoeducation about sleep,
stimulus control, and challenging beliefs and perception
of sleep. Bipolar patients may be prone to misperceive
sleep for wakefulness [3,32]. There will also be a focus
on challenging and correcting sleep state misperception
using cognitive and behavioral techniques [33]. Circadian
rhythm is likely to be disturbed in the included patients,
so there will be particular emphasis on stabilization of the
circadian rhythm. Chronotherapeutic interventions of light
therapy and gradual sleep phase advancement are currently
the best available treatment options for circadian rhythmdisturbances [34]. If necessary, these interventions will be
included, to stabilize the circadian rhythm. The treatment
will last for three to eight sessions. The therapists will be
two clinical psychologists and one psychiatrist. Therapists
will have received training in CBT-I and have one to nine
years of clinical experience with CBT-I. Patients will be
given checks for treatment credibility. Therapy sessions
will be checked for adherence to manual by having at least
two therapists present during treatment.
Withdrawal criteria
Patients will be withdrawn from the study if the clinician
finds that the patient is in need of, or better served with,
other treatment; if exclusion criteria are met; if the clin-
ical condition gets significantly worse according to the
clinicians’ judgment; or if patients withdraw their con-
sent. All patients prematurely discontinuing the trial will
be seen for a final evaluation. The date and reason for
discontinuation will be noted.
Sample size calculation
A-priori power calculations
The primary response variable, change in ISI score be-
tween baseline and endpoint, will be analyzed with the
independent samples t test at a significance level of α =
0.05. Prior studies of CBT-I for patients with mental disor-
ders and comorbid insomnia have found between-group
effect sizes in a range from d =1.1 to d = 1.6 on the ISI.
Thirty-six patients are required to have a 90% chance of
detecting a between-group effect size of d = 1.1 at a signifi-
cance level of α = 0.05. This corresponds to a change in
ISI score from 18 in the control group to 14 in the CBT-I
group given a standard deviation of 3.6.
In addition, secondary response variables of total sleep
time, sleep efficiency, and changes in polysomnography
parameters will be recorded. Daily and weekly variations
in mood and time to relapse to a new episode will also
be compared between the two groups.
Statistics
Categorical variables will be analyzed using chi-square
tests. Ordinal variables will be analyzed using nonpara-
metric tests in addition to using Student’s t tests, ana-
lysis of variance (ANOVA) and analysis of covariance
(ANCOVA) with baseline values as covariates. The time
to change in treatment for bipolar disorder will be ana-
lyzed using survival analysis. Linear mixed models will
be applied in analyses of treatment response. All patients
who fulfill baseline registration will be included in the
analysis of baseline characteristics. All subjects who re-
ceive at least one session of CBT-I and provide post-
baseline efficacy measurements will be included in efficacy
data analyses. Analyses including only patients fulfilling
the treatment will also be conducted.
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The study protocol has been approved by the Regional
Committee for Medical Research Ethics in Middle Norway.
Written informed consent will be obtained from all in-
cluded patients.Discussion
This study will test whether treatment with CBT-I can
provide improvement in sleep quality and will also be
one of the first to test the effects of CBT-I on patients
with insomnia and bipolar disorder. Insomnia is associ-
ated with several negative health outcomes in the gen-
eral population [7]. It is likely that patients with bipolar
disorder and insomnia, in addition to the same negative
consequences, have an increased risk of experiencing
new episodes of depression or (hypo) mania.
We are not aware of side effects related to CBT-I, but
as it is an untested treatment in bipolar disorder, we do
not know if it may trigger new episodes of depression or
mania [35]. The extensive study program may become a
potential problem for inclusion of participants and com-
pletion of study procedures. Motivational work will be all-
important before and during treatment in both groups.
Descriptions of quality of sleep in euthymic periods of
bipolar disorder are important for planning interven-
tions and improving monitoring for signs of recurrence
of new episodes of depression or (hypo) mania.
It is important to compare the value of diagnostic tools,
such as sleep diaries, actigraphs and polysomnography, in
order to improve the quality of diagnosis and possibly to
simplify the clinical practice of such tools [36].Trial status
Inclusion of patients will start in August 2013 and is ex-
pected to continue until January 2015 or until the neces-
sary number of participants has been included.
Abbreviations
ANCOVA: analysis of covariance; ANOVA: analysis of variance; BAI: Beck
Anxiety Inventory; CBT-I: cognitive behavioral therapy for insomnia; BDI: Beck
Depression Inventory; DBAS: Dysfunctional Attitudes and Beliefs about Sleep;
FFS: Flinders Fatigue Scale; IDWS: Insomnia Daytime Worry Scale;
IIS: Insomnia Interview Schedule; ISI: Insomnia Severity Index;
MADRS: Montgomery Åsberg Depression Rating Scale; MEQ: Morningness-
Eveningness Questionnaire; NEQ: Network Entry Questionnaire for Bipolar
Disorder; SCID: Structured Clinical Interview for DSM Disorders; SF-36: Short-
Form Health Survey; SHI: Sleep Hygiene Index; SRBQ: Sleep-Related Behaviors
Questionnaire; TAU: treatment as usual; YMRS: Young Mania Rating Scale.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
MKS, KKG, KL, TS, HK, and GM all conceptualized the study, participated in
the study design and contributed to the writing of the study protocol,
drafting and editing of this manuscript. GM is the overall study principal
investigator. All authors read and approved the final manuscript.Acknowledgements
The authors wish to thank Professor Allison Harvey, Department of
Psychology at the University of California, Berkeley, USA, and Professor Børge
Sivertsen at the National Institute of Public Health, Norway, for helpful
comments provided during the design of this study.
The study is funded by the Liaison Committee between the Central Norway
Regional Health Authority and the Norwegian University of Science and
Technology (NTNU), Department of Neuroscience at the Norwegian
University of Science and Technology (NTNU), and Østmarka Department of
Psychiatry at St. Olav’s University Hospital.
Received: 6 November 2013 Accepted: 6 January 2014
Published: 16 January 2014
References
1. WHO: The World Health Report 2001 - Mental Health. Genova: World Health
Organization: New Understanding, New Hope; 2001.
2. Wyatt RJ, Henter I: An economic evaluation of manic-depressive illness - 1991.
Soc Psychiatry Psychiatr Epidemiol 1995, 30(5):213–219.
3. Harvey AG: Sleep and circadian rhythms in bipolar disorder: seeking
synchrony, harmony, and regulation. Am J Psychiatry 2008, 165(7):820–829.
4. Perry A, Tarrier N, Morriss R, McCarthy E, Limb K: Randomised controlled
trial of efficacy of teaching patients with bipolar disorder to identify early
symptoms of relapse and obtain treatment. BMJ 1999, 318(7177):149–153.
5. Colom F, Vieta E, Sánchez-Moreno J, Palomino-Otiniano R, Reinares M,
Goikolea JM, Benabarre A, Martínez-Arán A: Group psychoeducation for
stabilised bipolar disorders: 5-year outcome of a randomised clinical trial.
Br J Psychiatry 2009, 194(3):260–265.
6. Task Force on DSM-IV, et al: Diagnostic and Statistical Manual of Mental
Disorders: DSM-IV-TR. Washington, DC: American Psychiatric Association: 4th
edition; 2000.
7. Ford DE, Kamerow DB: Epidemiologic study of sleep disturbances and
psychiatric disorders. An opportunity for prevention? JAMA 1989,
262(1):1479–1484.
8. Morin CM, Ware JC: Sleep and psychopathology. Appl Prev Psychol 1996,
5(4):211–224.
9. Pallesen S, Nordhus IH, Nielsen GH, Havik OE, Kvale G, Johnsen BH, Skjøtskift
S: Prevalence of insomnia in the adult Norwegian population. Sleep 2001,
24(7):771–779.
10. Smith MT, Perlis ML, Park A, Smith MS, Pennington J, Giles DE, Buysse DJ:
Comparative meta-analysis of pharmacotherapy and behavior therapy
for persistent insomnia. Am J Psychiatry 2002, 159(1):5–11.
11. Sivertsen B, Omvik S, Pallesen S, Bjorvatn B, Havik OE, Kvale G, Nielsen GH,
Nordhus IH: Cognitive behavioral therapy vs zopiclone for treatment of
chronic primary insomnia in older adults: a randomized controlled trial.
JAMA 2006, 295(24):2851–2858.
12. Manber R, Edinger JD, Gress JL, San Pedro-Salcedo MG, Kuo TF, Kalista T:
Cognitive behavioral therapy for insomnia enhances depression out-
come in patients with comorbid major depressive disorder and insom-
nia. Sleep 2008, 31(4):489–495.
13. Arnedt JT, Conroy DA, Armitage R, Brower KJ: Cognitive-behavioral therapy
for insomnia in alcohol dependent patients: a randomized controlled
pilot trial. Behav Res Ther 2011, 49(4):227–33.
14. Morin CM: Insomnia: Psychological Assessment and Management. New York:
Guilford Press; 1993.
15. Morken G, Vaaler AE, Folden GE, Andreassen OA, Malt UF: Age at onset of
first episode and time to treatment in in-patients with bipolar disorder.
Br J Psychiatry 2009, 194(6):559–560.
16. Suppes T, Leverich GS, Keck PE, Nolen WA, Denicoff KD, Altshuler LL,
McElroy SL, Rush AJ, Kupka R, Frye MA, Bickel M, Post RM: The stanley
foundation bipolar treatment outcome network. II. Demographics and
illness characteristics of the first 261 patients. J Affect Disord 2001,
67(1–3):45–59.
17. Åsberg M, Montgomery SA, Perris C, Schalling D, Sedvall G: A comprehensive
psychopathological rating scale. Acta Psychiatr Scand Suppl 1978, 271:5–27.
18. Young RC, Biggs JT, Ziegler VE, Meyer DA: A rating scale for mania:
reliability, validity and sensitivity. Br J Psychiatry 1978, 133:429–435.
19. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J: An inventory for
measuring depression. Arch Gen Psychiatry 1961, 4:561–71.
20. Beck AT, Epstein N, Brown G, Steer RA: An inventory for measuring clinical
anxiety: psychometric properties. J Consult Clin Psychol 1988, 56(6):893–7.
Steinan et al. Trials 2014, 15:24 Page 7 of 7
http://www.trialsjournal.com/content/15/1/2421. Altman EG, Hedeker D, Peterson JL, Davis JM: The altman self-rating mania
scale. Biol Psychiatry 1997, 42(10):948–55.
22. Buysse DJ, Ancoli-Israel S, Edinger JD, Lichstein KL, Morin CM: Recommen-
dations for a standard research assessment of insomnia. Sleep 2006,
29(9):1155–1173.
23. Carney CE, Buysse DJ, Ancoli-Israel S, Edinger JD, Krystal AD, Lichstein KL,
Morin CM: The consensus sleep diary: standardizing prospective sleep
self-monitoring. Sleep 2012, 35(2):287–302.
24. Morin CM, Belleville G, Belanger L, Ivers H: The insomnia severity index:
psychometric indicators to detect insomnia cases and evaluate treatment
response. Sleep 2011, 34(5):601–608.
25. McHorney CA, Ware JE Jr, Raczek AE: The MOS 36-item short-form health
survey (SF-36): II. Psychometric and clinical tests of validity in measuring
physical and mental health constructs. Med Care. 1993, 31(3):247–263.
26. Gradisar M, Lack L, Richards H, Harris J, Gallasch J, Boundy M, Johnston A:
The flinders fatigue scale: preliminary psychometric properties and
clinical sensitivity of a new scale for measuring daytime fatigue
associated with insomnia. J Clin Sleep Med 2007, 15((7)):722–728.
27. Horne JA, Ostberg O: A self-assessment questionnaire to determine
morningness-eveningness in human circadian rhythms. Int J Chronobiol
1976, 4(2):97–110.
28. Morin CM, Vallieres A, Ivers H: Dysfunctional beliefs and attitudes about
sleep (DBAS): validation of a brief version (DBAS-16). Sleep 2007,
30(11):1547–1554.
29. Ree MJ, Harvey AG: Investigating safety behaviours in insomnia: the
development of the Sleep-Related Behaviours Questionnaire (SRBQ).
Behav Change 2004, 21(1):26–36.
30. Kallestad H, Hansen B, Langsrud K, Hjemdal O, Stiles TC: Psychometric
properties and the predictive validity of the insomnia daytime worry
scale: a pilot study. Cogn Behav Ther 2010, 39(2):150–157.
31. Mastin DF, Bryson J, Corwyn R: Assessment of sleep hygiene using the
sleep hygiene index. J Behav Med 2006, 29(3):223–227.
32. Harvey AG, Schmidt DA, Scarna A, Semler CN, Goodwin GM: Sleep-related
functioning in euthymic patients with bipolar disorder, patients with
insomnia, and subjects without sleep problems. Am J Psychiatry 2005,
162(1):50–57.
33. Tang NK, Harvey AG: Altering misperception of sleep in insomnia:
behavioral experiment versus verbal feedback. J Consult Clin Psychol 2006,
74(4):767–776.
34. Bjorvatn B, Pallesen S: A practical approach to circadian rhythm sleep
disorders. Sleep Med Rev 2009, 13(1):47–60.
35. Kaplan KA, Harvey AG: Behavioral treatment of insomnia in bipolar disorder.
Am J Psychiatry 2013, 170(7):716–20.
36. Kaplan KA, Talbot LS, Gruber J, Harvey AG: Evaluating sleep in bipolar
disorder: comparison between actigraphy, polysomnography, and sleep
diary. Bipolar Disord 2012, 14(8):870–9.
doi:10.1186/1745-6215-15-24
Cite this article as: Steinan et al.: Cognitive behavioral therapy for
insomnia in euthymic bipolar disorder: study protocol for a randomized
controlled trial. Trials 2014 15:24.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
